PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNoticescategoryCategories
BuyersSuppliersNoticesCategories
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. UCB Pharma Ltd (primary)
UP

UCB Pharma Ltd (primary)

Berkshire
Large

UCB Pharma Ltd is a biopharmaceutical company with significant UK operations where it employs ~10% of its global workforce in R&D. The UK hosts one of three global research centres and a pre-manufacturing tech facility, with focus on neurology, immunology, rare diseases and gene therapies.

ucbpharma.co.uk ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£189.1m
Live
15
Buyers
5
12m
—
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities6
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts15 / 33
  • Top buyers5
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — UCB Pharma Ltd (primary)Updated 20 Jul 2026

At a glance · for buyers and watchdogs

UCB Pharma Ltd (primary) has won £189.1m across 5 public-sector buyers, with 15 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
15 of 33Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value · 1/5

Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.

◐ From supplier website
JobsNo commitment stated✓
SkillsNo commitment stated✓
Environment1 commitment✓
Tackling inequalityNo commitment stated✓
CommunityNo commitment stated✓
Environment · 1
  • WebsiteSustainability25% of revenue reinvested in biopharmaceutical R&D

Extracted automatically from web_search on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 6
Biopharmaceutical Research
Neurology
Immunology
Rare Diseases
Gene Therapies
Drug Development
Frameworks & DPS · 6 from notices
  • NHS England Framework Agreement: South of England (Tranche B)NHS England · £15.7m
  • NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder OpportunityNHS England · £8.4m
  • NHS Framework for the North of England, Branded MedicineNHS England · £7.7m
  • NHS South of England Branded Medicines - Tranche A - Contracts Finder Award NoticeNHS England · £7.2m
  • NHS Framework for the NHS London Region, Branded Medicines - Tranche ANHS England · £6.8m
  • NHS Framework Agreement - North of England - Tranche BNHS England · £5.6m

Extracted automatically from web_search on Jun 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 15 live · 18 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS Branded Medicines Tranche Framework for London and South of England
NHS England3360000001 Sept 2024£13.1m2 yrsLive
NHS South of England Branded Medicines - Tranche A - September 2023
NHS England3360000001 Sept 2023£7.6m2 yrsClosed
NHS London Branded Medicines - Tranche B - September 2023
NHS England3360000001 Sept 2023£6.4m2 yrsClosed
NHS Midland & East Branded Medicines, Tranche B & Annual Tranche
NHS England3360000001 Mar 2023£13.7m2 yrsClosed
NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche
NHS England3360000001 Mar 2023£9.0m2 yrsClosed
NHS Framework Agreement for South of England Branded - Tranche B and Annual
NHS England3360000001 Sept 2022£11.7m2 yrsClosed
NHS Framework Agreement for London, Branded Medicines - Tranche A and Annual
NHS England3360000001 Sept 2022£5.5m2 yrsClosed
NHS Framework for Midlands and East, Branded Medicines - Tranche A and Annual
NHS England3360000001 Mar 2022£7.0m2 yrsClosed
NHS Framework for the North of England, Branded Medicine
NHS England3360000001 Mar 2022£7.7m2 yrsClosed
NHS Framework, North of England, Branded Medicines-Tranche A and Annual Tranche
NHS England3360000001 Mar 2021£7.3m2 yrsClosed
Total live value £13.1m · mean award £5.7m1–10 of 33

Top buyers · 5 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
26 contracts
100%
since 2018
2
The NHS Commissioning Board (operating under the name of NHS England)
4 contracts
0%
3
eTenderwales
1 contract
0%
4
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
1 contract
0%
5
BELFAST HEALTH AND SOCIAL CARE TRUST
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire26 contracts
100%
North West4 contracts
0%
Wales2 contracts
0%
Northern Ireland1 contract
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). UCB Pharma Ltd (primary) highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m19
AB
AbbVie Ltd
Yes£95.2m13
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m22
UP
UCB Pharma Ltd (primary)
No——
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Due in -61d
Next due 22 May 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
00209905
Status
Active
Type
Private limited
Incorporated
24 Nov 1925
Reg. office
208 Bath Road, Slough, Berkshire, SL1 3WE
SIC codes
21100
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • REYNDERS, Nico Victor — director
    Appointed 01 Dec 2024
  • KHATRI, Yogesh — director
    Appointed 24 Jun 2013
  • PRICE, Steven Craig — director
    Appointed 19 Apr 2010
  • Celltech Group Limited — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
UCB PHARMA LIMITED
00209905 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.